We review long term results from the PHOTON Study with Eric Schneider, MD, Tennessee Retina, Nashville, TM.

We review the latest results from the Regenexbio sub retinal gene therapy program with Robert Avery MD, California Retina Consultants, Santa Barbara, CA

We discuss whether pegcetacoplan therapy of geography atrophy affects the progression of dry AMD with Paul Hahn MD PhD of PH Retina, Nanuet, New York.

We discuss the observation that resolution of retinal fluid at one month in eyes with nAMD treated with aflibercept 8mg may herald longer duration treatment intervals at week 96 with Michael Stewart,, MD, Knights Templar Professor of Ophthalmology, Mayo Clinic, Jacksonville, Florida.

We discuss the current state of the Good Days charitable foundation with Dr. Michael Lai, MD. PhD, Retina Group of Washington, Assistant Clinical Professor, Georgetown University School of Medicine

We discuss the long term results of the Oaks, Derby, and GALE studies looking at the benefit of early treatment of geographic atrophy in AMD with Dr. Roger Goldberg of Walnut Creek, California.

We discuss management of eyes with both geographic atrophy and neovascular AMD with Dr. Ted Leng of the Byers Eye Institute, Stanford University School of Medicine

We review the 6 month results of the Davio 2 trial of  the Durayvu TKI delivery system for maintenance therapy of neovascular AMD with Dr. Carl Regillo of Wills Eye Hospital.

We discuss the latest promising results from the GALE extension study of pegcetacoplan with Dr. Ashkan Abbey of Texas Retina Associates

We discuss the promising phase I results of the Helios trial studying AXPAXLI  TKI inhibitor implant for diabetic retinopathy with Dr. Dilsher Dhoot of California Retina Consultants.